ライフサイエンスコーパス: nucleotidase

1 rom ischemic neurologic injury by soluble 5'-nucleotidase.

2 ated by treatment of WT mice with soluble 5'-nucleotidase.

3 suppresses pain by functioning as an ecto-5'-nucleotidase.

4 mediated by selective inhibition of ecto-5'-nucleotidase.

5 potential targets of zinc other than ecto-5'-nucleotidase.

6 tional change in the secreted, soluble human nucleotidase.

7 F0115), referred to as proteasome-activating nucleotidase.

8 r agonists or reconstitution with soluble 5'-nucleotidase.

9 ctions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

10 with inhibition of SAH hydrolase but not 5'-nucleotidase.

11 rward ADP-mediated inhibition of the ecto-5'-nucleotidase.

12 ere all significantly reduced by blocking 5'-nucleotidase.

13 d this complex PAN for proteasome-activating nucleotidase.

14 tions in the same gene, NT5C2, encoding a 5'-nucleotidase.

15 pecifically blocked by parasite secretory 5'-nucleotidase.

16 indicating significant breakdown by soluble nucleotidases.

17 from released ATP through a cascade of ecto-nucleotidases.

18 PAP) phosphatase (gPAPP) and Bisphosphate 3'-nucleotidase 1 (Bpnt1).

19 the amount of transcript of Ca(2+)-activated nucleotidase 1 (CANT1), an endoplasmic reticulum (ER)-Go

20 Human soluble calcium-activated nucleotidase 1 (hSCAN-1) is the human homologue of solub

21 Human soluble calcium-activated nucleotidase 1 (hSCAN-1) represents a new family of apyr

22 pe 1 and identified CANT1 (calcium activated nucleotidase 1) mutations as responsible for DBQD type 1

23 hSCAN-1 for human soluble calcium-activated nucleotidase-1, was expressed in bacteria, refolded from

24 ysis revealed that Mup44 is the cytosolic 5'-nucleotidase 1A (cN1A).

25 ntire human proteome identified cytosolic 5'-nucleotidase 1A (cN1A; NT5C1A) as the likely 43 kDa IBM

26 Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing mode

27 escription of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially im

28 method for microassay of the activity of 5'-nucleotidase (5'-ND) and adenosine deaminase (ADA) in th

29 We demonstrate that soluble 5'-nucleotidase (5'-NT) and alkaline phosphatase (AP) media

30 uster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

31 5' nucleotidase (5'N) is a major source of the vasogenic su

32 hat purified, recombinant human cytosolic 5'-nucleotidases (5'-NTs) CN-II and CN-III, but not CN-IA,

33 enzymatic activity assays indicated that 5'-nucleotidase (5NT), rather than AP, was responsible for

34 nce factor, which we termed streptococcal 5'-nucleotidase A (S5nA).

35 se estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are f

36 bcellular location and the mechanism of ecto-nucleotidase activation, we expressed human NTPDase3 in

37 of several apyrase conserved regions for the nucleotidase activities of the NTPDases.

38 n X-100 detergent inhibition of Ca-dependent nucleotidase activities while greatly attenuating Triton

39 tyrosine resulted in dramatically increased nucleotidase activities, while mutagenesis of aspartic a

40 ting Triton X-100 inhibition of Mg-dependent nucleotidase activities.

41 se6-transfected COS-1 cells were assayed for nucleotidase activities.

42 d intrinsic magnesium-dependent bisphosphate nucleotidase activity (BPntase), which removed the 3'-ph

43 Given the high nucleotidase activity and apparently normal receptor sig

44 dentified a novel S. pyogenes enzyme with 5'-nucleotidase activity and immune evasion properties.

45 n had small, but detectable reduction in its nucleotidase activity and nucleotide binding affinity.

46 Collectively, our data support a role for 3'-nucleotidase activity and PAP metabolism in aspects of l

47 These results indicate that the lack of ecto-nucleotidase activity exhibited by NTPDase2 beta and -2

48 NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance

49 pounds induced a strong inhibition of the 5'-nucleotidase activity in vitro, and the most potent ones

50 zymes possess nicotinamide mononucleotide 5'-nucleotidase activity in vitro.

51 cleared -Pi culture medium as a source of 3'-nucleotidase activity indicates that cyclic nucleotide p

52 The NudP ecto-5'-nucleotidase activity is reminiscent of the reactions pe

53 ADPase activity, further indicating that the nucleotidase activity of CAN is linked to its quaternary

54 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown to

55 d-lineage cells is attributed in part to the nucleotidase activity of the SAM-domain and HD-domain co

56 ant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucleoside 5

57 not occur in bacteria are not necessary for nucleotidase activity or proper folding of this human ap

58 ght responses via its 3'(2'),5'-bisphosphate nucleotidase activity rather than its inositol polyphosp

59 hange in the divalent cation requirement for nucleotidase activity relative to the wild-type and the

60 In COS-7 cells, 5'-nucleotidase activity was not rate-limiting for inosine

61 In H9c2 cells, in which 5'-nucleotidase activity was rate-limiting, only cN-II over

62 Accordingly, exogenous nucleotidase activity was required to fully preserve P2X

63 We show that cNIII-like also displays 5' nucleotidase activity with a high affinity for m(7)GMP.

64 cken liver ecto-ATPDase cDNA express an ecto-nucleotidase activity with characteristics similar to th

65 the relationship between the FRY1-associated nucleotidase activity, a step in the pathway for sulfur

66 e kinase (Ndk), adenylate kinase (Ak) and 5'-nucleotidase activity, the level of secretion of the 5'-

67 mma, produced a protein completely devoid of nucleotidase activity, while mutation of Asn443 to Asp r

68 ate-1-phosphatase and 3'(2'),5'-bisphosphate nucleotidase activity.

69 nformational change in hSCAN-1 necessary for nucleotidase activity.

70 ine 271 resulted in enzymes with very little nucleotidase activity.

71 l-nucleotide substrate complex necessary for nucleotidase activity.

72 thyroxine concentrations and mononuclear 5'-nucleotidase activity.

73 ectable deoxyribonuclease, ribonuclease, and nucleotidase activity.

74 and ACR IV (Gly 221) also severely disrupted nucleotidase activity.

75 expressed ecto-apyrase completely devoid of nucleotidase activity.

76 e recombinant and native proteins possess 5'-nucleotidase activity; hence, the protein has been calle

77 ono Q column demonstrates the presence of 5'-nucleotidase, adenylate kinase, and a putative ATP reduc

78 , thus raising the question whether the ecto-nucleotidases affect the ATP-dependent processes in thes

79 th bleomycin and supplemented with exogenous nucleotidase also exhibited reduced inflammation.

80 thylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+) currents

81 king A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellular AMP

82 tudy tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conversion o

83 n of the apical plasma membrane proteins, 5'-nucleotidase and aminopeptidase N in lysosomal vacuoles.

84 NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosine from e

85 id rafts marked by GPI-anchored proteins (5' nucleotidase and folate receptor).

86 Here we report a role for 3'-nucleotidase and its substrate, 3'-phosphoadenosine 5'-p

87 3'-NT/NU-expressed protein possessed both 3'-nucleotidase and nuclease activities.

88 HD-domain phosphohydrolases have nucleotidase and phosphodiesterase activities and play i

89 SNPs at the 5'-nucleotidase and xanthine oxidase genes influence the ri

90 displayed high selectivity versus other ecto-nucleotidases and ADP-activated P2Y receptors.

91 asomes associated with proteasome-activating nucleotidases and membrane-associated Lon proteases.

92 peptide, vascular endothelial growth factor, nucleotidases and nucleases, nerve growth factor, and L-

93 w that NR is constantly produced by multiple nucleotidases and that the intracellular NR pools are li

94 e activity, the level of secretion of the 5'-nucleotidase (and/or ATPase/phosphatase) appears to be l

95 e following secreted exoenzymes: apyrase, 5'-nucleotidase, and adenosine deaminase.

96 adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adenosine rec

97 rate nucleoside diphosphate kinase (Ndk), 5' nucleotidase, and adenylate kinase (Ak) activities.

98 n phosphatases, purple acid phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

99 e, protein serine/threonine phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

100 oblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

101 , initially classified as an IMP-specific 5'-nucleotidase, and Sdt1, initially classified as a pyrimi

102 s unrelated in sequence to more well-studied nucleotidases, and very little is known about the enzyma

103 g treatment with a high concentration of the nucleotidase apyrase (17 +/- 5 pA/pF for 10 IU/ml and 11

104 oliferation were induced by the soluble ecto-nucleotidase apyrase and the P2 receptor inhibitor suram

105 of Madin-Darby canine kidney cells with the nucleotidase apyrase decreases basal arachidonic acid re

106 Both these ecto-nucleotidases are expressed by Presynaptic cells, as sho

107 secretory pathway, the active sites of ecto-nucleotidases are located in the lumen of vesicular comp

108 dt1, initially classified as a pyrimidine 5'-nucleotidase, are additionally responsible for dephospho

109 enzymatic activation of hSCAN-1 detected by nucleotidase assay.

110 ammalian COS-1 cells and characterized using nucleotidase assays as well as size exclusion, anion exc

111 muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

112 Bisphosphate 3'-nucleotidase (BPNT-1) is a lithium-sensitive phosphatase

113 Bisphosphate 3'-nucleotidase (BPNT1 in mammals and Met22/Hal2 in yeast)

114 ssion of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD39L1), in

115 tic activity and biological function in this nucleotidase by mutating isoleucine 170, which is locate

116 Human calcium-activated nucleotidase (CAN) exists as both a membrane-bound form

117 analysis demonstrated that NBD1 is a general nucleotidase capable of hydrolysis of ATP, CTP, GTP, and

118 expression of the immunosuppressive ATP ecto-nucleotidase CD39.

119 llular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after thoracic

120 The cell surface nucleotidase CD73 is an immunosuppressive enzyme involve

121 es AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

122 mmunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

123 nosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

124 "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhibitory f

125 tive channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

126 ed to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates surface a

127 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosphohydrol

128 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in extra

129 on of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrier f

130 ning, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive neurons an

131 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid body basal

132 Ecto-5'-nucleotidase (CD73) is a central surface enzyme generati

133 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for the pro

134 Ecto-5'-nucleotidase (CD73) is central to the generation of extr

135 Ecto-5'-nucleotidase (CD73) is expressed abundantly on the apica

136 Ecto-5'-nucleotidase (CD73) is the main enzyme responsible for t

137 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extracellular

138 m, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

139 Ecto-5'-nucleotidase (CD73) on immune cells is emerging as a cri

140 y response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart failure

141 to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

142 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in conjunctio

143 (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to threefold

144 han in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

145 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts extracellul

146 e present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates adenosine,

147 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the major enzym

148 the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and organ func

149 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of extracell

150 Ecto-5'-nucleotidase (CD73), the enzyme that generates adenosine

151 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert ex

152 nophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contribution of CD7

153 of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly lower in C5

154 terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

155 sphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

156 k) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme responsible

157 ate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymph n

158 osphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 patien

159 and characterized a novel human cytosolic 5'-nucleotidase (cN-I) that potentially may have an importa

160 senger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchial

161 Two, cloned cytosolic 5'-nucleotidases (cN-I and cN-II) have been implicated in A

162 been identified as targeting cytoplasmic 5' nucleotidase (cN1A; NT5C1A), a protein involved in nucle

163 uggest that P2 nucleotide receptors and ecto-nucleotidases compete for a limited pool of endogenously

164 s related archaeal 20S proteasomes require a nucleotidase complex such as PAN to mediate the energy-d

165 This indicates that the 5'-nucleotidase contributes to but is not solely responsibl

166 ame time, surface-expressed ectoapyrases and nucleotidases convert extracellular nucleotides to adeno

167 urine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, purine nucleoside phosphoryla

168 of one of these hits, confirmed NT5C (5',3'-Nucleotidase, Cytosolic) as a novel AKT substrate, with

169 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-deficient

170 timuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A1-adenos

171 of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(+) T reg

172 IMP-specific, High Km 5'-nucleotidase (EC 3.1.3.5) is an ubiquitous enzyme, the a

173 the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphatase

174 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metall

175 duals, siRNA of tetraspanin 33 (TSPAN33), 5'-nucleotidase, ecto (NT5E), transmembrane emp24 protein t

176 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extr

177 cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

178 eotidase II gene (NT5C2), which encodes a 5'-nucleotidase enzyme that is responsible for the inactiva

179 Disruption of TG neuronal ecto-nucleotidase expression and axonal terminal localization

180 bset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence intensi

181 rong in salivary-expressed members of the 5'-nucleotidase family of arthropods because of constraints

182 Members of the 5'nucleotidase family were recruited for salivary expressi

183 while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

184 ineering the soluble human calcium-activated nucleotidase for clinical applications.

185 Here we describe a novel 5' nucleotidase from Drosophila that cleaves m(7)GMP to 7-m

186 d to the redistribution of syntaxin 2 and 5' nucleotidase from the apical membrane to subapical punct

187 Disruption of the yeast 3'-nucleotidase gene or treatment of cells with lithium res

188 Two SNPs at the 5'-nucleotidase gene were associated with NCPH: rs11191561

189 nucleotides, mammals possess two related 3'-nucleotidases, Golgi-resident 3'-phosphoadenosine 5'-pho

190 CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did not affe

191 However, inhibition of 5'-nucleotidase had no effect on ATP/ADP/UTP-induced phosph

192 HUVEC express NTPDases, as well as 5'-nucleotidase; hence, nucleotides can be metabolized to a

193 ign potential inhibitors of the cytosolic 5'-nucleotidase II (cN-II), which has been recognized as an

194 ast to cNIII-like, cNIII and human cytosolic nucleotidase II do not accept m(7)GMP as a substrate.

195 g, we identify mutations in the cytosolic 5'-nucleotidase II gene (NT5C2), which encodes a 5'-nucleot

196 ABL1 fusions, NOTCH1/FBXW7, and cytosolic 5'-nucleotidase II gene mutations identify patient groups w

197 Cytosolic 5'-nucleotidase III (cN-III) is responsible for selective d

198 e similarity to two human enzymes, cytosolic nucleotidase III (cNIII) and the previously uncharacteri

199 and the previously uncharacterized cytosolic nucleotidase III-like (cNIII-like).

200 supported by comparison to YfdR, another 5'-nucleotidase in E. coli.

201 role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

202 anism for regulation of the activity of this nucleotidase in the physiological setting of the endopla

203 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog alpha,b

204 rectly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

205 a 2-step enzymatic reaction mediated by ecto-nucleotidases, including CD73 and ecto-nucleoside tripho

206 Both parasite secreted products and the 5'-nucleotidase inhibit ADP-induced release of mast cell pr

207 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene adenosine-5

208 inally, this response was potentiated by the nucleotidase inhibitor 6-N,N-diethyl-beta-gamma-dibromom

209 beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP prevent

210 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200 mic

211 s greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200 mic

212 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significantly dim

213 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellular ATP

214 enosine activity was clamped by combining 5'-nucleotidase inhibitor with A1-agonist to determine whet

215 sine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene adenosine 5

216 osine A1 receptor blocker, A1-agonist, or 5'-nucleotidase inhibitor.

217 transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine significantly

218 C infection by testing the effect of ecto-5'-nucleotidase inhibitors.

219 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosine, whic

220 adation of secreted ATP by ecto- and soluble nucleotidases is a possible explanation.

221 This family of nucleotidases is unrelated in sequence to more well-stud

222 e hexamer, whereas the proteasome-activating nucleotidase-like contact is required to close the ring.

223 the PO4 moieties from ATP, likely with a 5'-nucleotidase-like enzyme rather than alkaline phosphatas

224 hatases (CCAPs), which are nonspecific 5',3'-nucleotidases localized to the bacterial outer membrane.

225 Use of soluble 5'-nucleotidase may be a potential therapeutic for hepatic

226 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation from the

227 These vertebrate nucleotidases may play a role in protein glycosylation.

228 one proposed for the catalytic mechanisms of nucleotidase members of the haloacid dehalogenase family

229 Such fractions, harboring 5' nucleotidase, Ndk, and presumably other ATP-utilizing en

230 B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and highlig

231 at specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor activation

232 We show that presentation of Lm nucleotidase (NT)-OVA is TAP independent in vivo and in

233 ecreted chimeric protein with L. donovani 3' nucleotidase (NT-OVA).

234 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP to adeno

235 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in STP neu

236 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored protein

237 )R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphatase

238 mulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, prostatic ac

239 ial P2Y receptors via expression of the ecto-nucleotidase NTPDase2.

240 Cell-surface nucleotidases (NTPDases) contain 10 invariant cysteine r

241 The 3'-nucleotidase/nuclease (3'-NT/NU) is a surface enzyme uni

242 s unique, bi-functional, surface membrane 3'-nucleotidase/nuclease (Cl 3'NT/NU) activity by approxima

243 encoding a new member of this family, the 3'-nucleotidase/nuclease (Ld3'NT/NU) of the parasitic proto

244 (20.8%) and the C-terminal domain of the 3' nucleotidase of Leishmania donovani (33.7%).

245 nly found in canonical proteasome-activating nucleotidases of the PAN/ARC/Rpt group, which are absent

246 lyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors were prote

247 ckade and reduced by apyrase inactivation of nucleotidases, P2 receptor antagonists, tetrodotoxin (TT

248 s stimulated using the proteasome-activating nucleotidase (PAN) ATPase complex.

249 ing of two H. volcanii proteasome-activating nucleotidase (PAN) genes (panA and panB).

250 anA and panB) encoding proteasome-activating nucleotidase (PAN) proteins closely related to the regul

251 with the AAA+ Cdc48 or proteasome-activating nucleotidase (PAN) unfoldases.

252 mohexameric complex of proteasome-activating nucleotidase (PAN), is responsible for target protein re

253 mohexameric complex of proteasome-activating nucleotidase (PAN).

254 d moiety of ubiquitin is a substrate for the nucleotidase/phosphohydrolase, resulting in either trans

255 polypeptide: an ADP-ribosyltransferase and a nucleotidase/phosphohydrolase.

256 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulating this

257 We suggest that the m(7)G-specific nucleotidases protect cells against undesired salvage of

258 ii encodes two related proteasome-activating nucleotidase proteins, PanA and PanB, with PanA levels p

259 target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors and metast

260 oteasomes and the PAN (proteasome-activating nucleotidase) regulatory complex, a homolog of the eukar

261 Thus, chronic administration of nucleotidase-resistant phosphonates conferred a benefici

262 structures of ClpX and proteasome-activating nucleotidase, respectively.

263 Intranasal instillations of exogenous nucleotidase restored the ability of lungs of CD73(-/-)

264 nstitution of cd73(-/-) mice with soluble 5'-nucleotidase resulted in complete restoration of hepatop

265 Inhibition of ecto-nucleotidases resulted in ATP accumulation at a rate of

266 Mutations in ushA, encoding a predicted 5'-nucleotidase, resulted in accumulation of flavin adenine

267 In addition, expression of the full-length nucleotidase revealed that this membrane-bound form can

268 karya or with the AAA+ proteasome-activating nucleotidase ring in some archaea.

269 rate of extracellular ATP hydrolysis by ecto-nucleotidase(s).

270 Like other 5'-nucleotidases, S5nA requires divalent cations and was ac

271 and metabotropic P2 receptors, exo- and ecto-nucleotidases, second messengers, and gap junctions.

272 ed a cell wall-anchored protein harbors a 5'-nucleotidase signature sequence and evidence strongly in

273 y facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

274 data indicate that the accumulation of a 3'-nucleotidase substrate, such as PAP, mediates the toxici

275 rocess of association and dissociation of 5'-nucleotidase subunits.

276 ype-1 (ENTPD1) is the dominant vascular ecto-nucleotidase that catalyzes the phosphohydrolysis of ext

277 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phosphohydrolys

278 y the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine introduced a

279 ce that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to test whe

280 CD73 is a cell surface 5'-nucleotidase that converts AMP to adenosine, an immune s

281 purinergic signaling are determined by ecto-nucleotidases that control ATP degradation and adenosine

282 ecrease in activity of Ca(2+)-dependent ecto-nucleotidases that degrade ATP.

283 hese compounds have been well described, the nucleotidases that may mediate drug resistance through d

284 tly identified dimeric nature of the soluble nucleotidase, the dimer interface contains a central cor

285 However, unlike some membrane-bound ecto-nucleotidases, the eNTPDase6 activity was not specifical

286 ndothelial cell-specific molecule-1, 5'-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, e

287 Eukaryotic pyrimidine 5'-nucleotidase type 1 (P5N-1) catalyzes dephosphorylation

288 mals express a protein homologous to soluble nucleotidases used by blood-sucking insects to inhibit h

289 treatment of wild-type mice with soluble 5'-nucleotidase was associated with significantly lower lev

290 has been named PAN for proteasome-activating nucleotidase was characterized from the hyperthermophile

291 The secreted 5'-nucleotidase was identified as a protein with an apparen

292 nephropathy, whereas treatment with soluble nucleotidase was therapeutic.

293 ycophosphatidylinositol-anchored protein, 5'-nucleotidase, were observed, suggesting that increased m

294 s demonstrate that NBD1 of ABCR is a general nucleotidase, whereas NBD2 is a specific ATPase.

295 erase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, n

296 sphohydrolase (E-NTPDase 8) are cell surface nucleotidases with two transmembranous domains, one each

297 l function to be a nuclease, phosphatase, or nucleotidase, with a requirement for some metal ions.

298 in phosphohydrolase, the Escherichia coli 5'-nucleotidase YfbR.

299 s (ndk, pykA, or pykF) and the gene for a 5'-nucleotidase (yfbR).

300 The nucleotidase YjjG is critical for this step.